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Response to “Radiation Therapeutic Gain 
and Asian Botanicals,” by Stephen Sagar
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Abstract
Numerous botanical agents, many of which are used in whole medical system practices (i.e. traditional Chinese medicine, 
Ayurvedic medicine, etc.), have been shown to exhibit radiomodifying effects on tumors and normal tissues in-vitro and in-
vivo studies. Some of these agents can enhance the therapeutic gain of radiation therapy by either acting as a radiosensitizer 
to tumor cells and/or as a radioprotector to normal cells. Botanical agents are comprised of multiple phytochemical 
compounds that may work individually or synergistically to not only improve radiation therapy outcomes, but may also 
exhibit a variety of anti-cancer effects as well. It will be important to evaluate these botanicals for efficacy, tumor specificity, 
and safety profiles before they can be recommended during radiation therapy. 
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The use of nontoxic, inexpensive botanical agents to cause 
a radiomodifying response to enhance therapeutic gain (ie, 
radiosensitization of tumors and/or radioprotection of 
normal tissues) is compelling. In his article published in 
this issue, “Can the Therapeutic Gain of Radiotherapy be 
Increased by Concurrent Administration of Asian Botani-
cals?”, Dr. Stephen Stepehen Sagar addresses the data, 
mechanisms of action, and rationale supporting the use of 
botanical agents in radiation therapy.1 Unfortunately, the 
literature is very limited in the number and quality, particu-
larly in humans, of experiments that have attempted to 
address this approach. Theoretical mechanisms of action 
for enhancing the therapeutic gain are many (ie, preferen-
tial uptake of antioxidant molecules into normal tissues vs 
tumor tissues, decreased intratumoral DNA repair, 
decreased intratumoral production of endogenous anti-
oxidants, inhibition of the cell cycle in radiosensitive 
phases, etc). In addition to their radiomodifying effects, 
some botanical agents have also been shown to exhibit 
nonradiomodifying antitumor effects such as upregulating 
immune modulating cytokines (ie, Panax ginseng,2 etc), 
promoting apoptosis (ie, ginger extracts3,4), and inhibiting 
angiogenesis (ie, EGCG,5 curcumin,6,7 etc). Taking 
advantage of multiple antitumor mechanisms using botani-
cal agents during radiation therapy is not dissimilar to 
conventional pharmacologic approaches that have simi-
larly employed multiple chemotherapeutic, biologic, and/
or immune modulating agents during radiation therapy. 
The theoretical advantages of botanical agents over 
conventional agents are their potentially lower side-
effect profiles and significantly lower cost.
In addition to their antitumor effects, botanical agents 
have also been employed to help mitigate untoward side 
effects frequently encountered in oncology. Fatigue is one 
of the most common complaints in patients during and 
after chemotherapy and/or radiation therapy. Barton et al9 
recently published the findings of a phase 3 study that found 
that ginseng (Panax quinquefolius) seemed to exhibit 
positive effects in helping relieve cancer-related fatigue. 
Numerous other antitumor botanical compounds have also 
shown promise in relieving commonly experienced symp-
toms in oncology (ie, ginger, Zingiber officinale, has 
recently been reported to help reduce chemotherapy-induced 
nausea,10 etc).
As discussed by Sagar, it is important that well-designed 
and rigorously conducted studies are undertaken to further 
investigate a wide range of questions that have yet to be 
answered: elucidating the various mechanisms of action, 
doses, routes of administration, effects of combination ther-
apies, toxicity profiles, whole compound versus isolated 
1Uniformed Services University of the Health Sciences, Bethesda, MD, USA
2Indiana University, Indianapolis, IN, USA
Corresponding Author:
Brian D. Lawenda, Radiation Oncology Department, Naval Medical 
Center San Diego, 34800 Bob Wilson Drive, San Diego, CA 92134, USA
Email: brian.lawenda@med.navy.mil
Lawenda	 15
bioactive agent, and so on. One of the primary concerns of 
oncologists is that of interaction of botanical substances 
with conventional therapies. It is critical that experiments 
are conducted to define whether specific botanical com-
pounds reduce the efficacy of conventional treatments or 
increase toxicity. Furthermore, standardized production of 
quality botanical compounds is imperative in assuring that 
the ingredients, amount, and activity are the same in each 
dose administered.
What Should We Recommend 
to Our Patients Now?
The lack of rigorously conducted studies examining the effects 
of botanicals during radiation therapy is a significant problem 
for oncologists. Primum non nocere is the “golden rule” that 
we all learned in medical school and is the conservative and 
safe approach to most therapies that are considered prior to 
recommending them to our patients. I highly encourage my 
patients to first discuss with me any supplemental, isolated 
botanical compounds that they might be considering taking 
so that we can review the latest data available. Increasingly, 
well-conducted studies are being reported to help us better 
understand these complex questions.
In general, consuming whole foods that contain the botani-
cal compounds of interest are likely safe and theoretically 
may be more effective than the isolated extracts taken as a 
high-dose supplement. Thousands of phytochemical com-
pounds have been identified that exhibit numerous anticancer 
effects on tumor cells and their microenvironment. A cur-
rently popular hypothesis, and one that I believe, is that by 
consuming a diet consisting of foods that contain a variety 
of phytochemicals, individuals may be able to make their 
body less conducive to tumor development, growth, and 
progression by acting on many anticancer pathways. 
Combining a whole foods anticancer approach concurrently 
with radiation therapy is one that I encourage in my patients.
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